SHINE Technologies and WARF Therapeutics today announced pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin.

According to a release, the studies showed that WT-7695 and ART-101, which are treatments that leverage SHINE’s non-carrier added Lu-177 chloride called Illumira, have the potential to increase life span and be more effective in treating kidney and prostate cancer.

“This is further validation that Ilumira is more effective than the standard of care for cancer treatment,” SHINE CEO Greg Piefer said in a statement. “We’re thrilled to support the University of Wisconsin in its groundbreaking work and excited to play even a small role in world-changing programs like these. We look forward to our continued collaboration to create a brighter future for patients.”

The group plans to move WT-7695 and ART-101 onto human trials within the next year.